Article citationsMore>>

Boehringer Ingelheim (2024) CDSCO Approves SPEVIGO® (Spesolimab)—The First Treatment Option for Generalized Pustular Psoriasis Flares in Adults.
https://www.boehringer-ingelheim.com/in/cdsco-approves-spevigo-Spesolimab-first-treatment-option-generalized-pustular-psoriasis-flares

has been cited by the following article:

SCIRP Newsletter
Copyright © 2006-2026 Scientific Research Publishing Inc. All Rights Reserved.
Top